Treatment of Essential Thrombocythemia with History of Arterial Thrombosis
In essential thrombocythemia (ET), a prior arterial thrombotic event is a defining criterion for high-risk classification at any age. Identifying this history is the first step in selecting the appropriate treatment intensity.
Clinical Scenario
A history of arterial thrombosis at any age places the patient in the high-risk ET group. Thrombosis risk stratification in ET spans four categories — very low, low, intermediate, and high — with a prior arterial thrombotic event as one of the key determinants of high-risk status.
Treatment Approach
The first-line strategy for high-risk ET in this setting combines cytoreductive therapy with antiplatelet treatment. The specific agents, dosing schedule, and monitoring plan are detailed in the full structured protocol.
Treatment Goal
Platelet count maintained within the normal range.
References
DOI: 10.1002/ajh.27216
- Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).
- We also believe it is reasonable to use twice-daily aspirin in patients with arterial thrombosis if they are older or harbor JAK2 mutations or in the presence of CV risk factors (Figure 5).
- In addition to low-dose aspirin, high-risk patients with ET should receive HU, as first-line cytoreductive drug of choice, in order to minimize their risk of thrombosis (starting dose 500 mg BID).
- The dose of HU is titrated to keep platelet count in the normal range.
View source ↗